DURECT Corporation Reports Q1 2025 Financial Results

DURECT Corporation ( (DRRX) ) has released its Q1 earnings. Here is a breakdown of the information DURECT Corporation presented to its investors.

DURECT Corporation is a late-stage biopharmaceutical company focused on developing epigenetic therapies targeting dysregulated DNA methylation to treat serious conditions, with a lead drug candidate, larsucosterol, aimed at alcohol-associated hepatitis (AH).

In its latest earnings report, DURECT Corporation highlighted its ongoing efforts to initiate a Phase 3 trial for larsucosterol in treating severe AH, following promising Phase 2b trial results published in NEJM Evidence. The company is actively seeking funding to support this trial and exploring potential business development opportunities.

Financially, DURECT reported a net loss of $4.2 million for the first quarter of 2025, an improvement from the $7.6 million loss in the same period in 2024. Revenues were slightly down at $0.3 million compared to $0.5 million the previous year. The company’s cash and investments stood at $8.4 million as of March 31, 2025, down from $12.0 million at the end of 2024.

Strategically, DURECT is planning a registrational Phase 3 trial for larsucosterol, with a focus on 90-day survival as the primary endpoint. The trial design has incorporated feedback from the FDA and learnings from the Phase 2b AHFIRM trial. Additionally, the company is evaluating options for commercializing POSIMIR after the termination of its licensing agreement with Innocoll Pharmaceuticals.

Looking ahead, DURECT Corporation remains committed to advancing the development of larsucosterol for AH, with the potential for other indications. The company’s management is focused on securing the necessary funding to initiate the Phase 3 trial and exploring strategic partnerships to enhance its financial and operational capabilities.